These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33769184)

  • 1. Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.
    Mangangcha IR; Brojen Singh RK; Lebeche D; Ali S
    J Biomol Struct Dyn; 2022 Oct; 40(17):7868-7884. PubMed ID: 33769184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
    Zhu J; Wu Y; Xu L; Jin J
    Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational prediction and experimental validation of the activator function of C2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxyxanthone on pancreatic and hepatic hexokinase.
    Shinkafi TS; Kaushik A; Mahmood A; Tiwari AK; Alam MM; Akhter M; Gupta D; Ali S
    J Biomol Struct Dyn; 2020 Jul; 38(10):2976-2987. PubMed ID: 31366304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modeling and molecular dynamics simulation studies of the GSK3β/ATP/substrate complex: understanding the unique P+4 primed phosphorylation specificity for GSK3β substrates.
    Lu SY; Jiang YJ; Zou JW; Wu TX
    J Chem Inf Model; 2011 May; 51(5):1025-36. PubMed ID: 21495724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theoretical studies on the selective mechanisms of GSK3β and CDK2 by molecular dynamics simulations and free energy calculations.
    Zhao S; Zhu J; Xu L; Jin J
    Chem Biol Drug Des; 2017 Jun; 89(6):846-855. PubMed ID: 27863047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel and highly potential inhibitors of glycogen synthase kinase 3-beta (GSK-3β) through structure-based pharmacophore modeling, virtual computational screening, docking and in silico ADMET analysis.
    Benghanem S; Mesli F; Fatima Zohra HA; Nacereddine C; Hadjer C; Abdellatif M
    J Biomol Struct Dyn; 2024 Sep; 42(14):7091-7106. PubMed ID: 37498130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of binding affinity of 1,2-diphenyline ketone analogues at adenosine triphosphate binding site of glycogen synthase kinase-3β: a molecular docking and dynamic simulation study.
    Dinakar S; Gurubarath M; Dhananjayan K
    J Biomol Struct Dyn; 2023 Jul; 41(11):4847-4862. PubMed ID: 35543239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of double mutations K214/A-E215/Q of FRATide on GSK3β: insights from molecular dynamics simulation and normal mode analysis.
    Lu SY; Jiang YJ; Zou JW; Wu TX
    Amino Acids; 2012 Jul; 43(1):267-77. PubMed ID: 21912861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How calcium inhibits the magnesium-dependent kinase gsk3β: a molecular simulation study.
    Lu SY; Huang ZM; Huang WK; Liu XY; Chen YY; Shi T; Zhang J
    Proteins; 2013 May; 81(5):740-53. PubMed ID: 23184735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.
    Bhat R; Xue Y; Berg S; Hellberg S; Ormö M; Nilsson Y; Radesäter AC; Jerning E; Markgren PO; Borgegård T; Nylöf M; Giménez-Cassina A; Hernández F; Lucas JJ; Díaz-Nido J; Avila J
    J Biol Chem; 2003 Nov; 278(46):45937-45. PubMed ID: 12928438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural modeling of GSK3β implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs.
    Balasubramaniam M; Mainali N; Bowroju SK; Atluri P; Penthala NR; Ayyadevera S; Crooks PA; Shmookler Reis RJ
    Sci Rep; 2020 Oct; 10(1):18326. PubMed ID: 33110096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of two potential glycogen synthase kinase 3β inhibitors for the treatment of osteosarcoma.
    Lu K; Wang X; Chen Y; Liang D; Luo H; Long L; Hu Z; Bao J
    Acta Biochim Biophys Sin (Shanghai); 2018 May; 50(5):456-464. PubMed ID: 29546355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative splicing of the porcine glycogen synthase kinase 3β (GSK-3β) gene with differential expression patterns and regulatory functions.
    Wang L; Zuo B; Xu D; Ren Z; Zhang H; Li X; Lei M; Xiong Y
    PLoS One; 2012; 7(7):e40250. PubMed ID: 22792253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Mechanistic Characterization of a Peptide Inhibitor of Glycogen Synthase Kinase (GSK3β) Derived from the Disrupted in Schizophrenia 1 (DISC1) Protein.
    Saundh SL; Patnaik D; Gagné S; Bishop JA; Lipsit S; Amat S; Pujari N; Nambisan AK; Bigsby R; Murphy M; Tsai LH; Haggarty SJ; Leung AK
    ACS Chem Neurosci; 2020 Dec; 11(24):4128-4138. PubMed ID: 33253521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer.
    Liao X; Thrasher JB; Holzbeierlein J; Stanley S; Li B
    Endocrinology; 2004 Jun; 145(6):2941-9. PubMed ID: 14988390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of active fraction of glycogen synthase kinase 3beta in cancer cells by nonradioisotopic in vitro kinase assay.
    Mai W; Miyashita K; Shakoori A; Zhang B; Yu ZW; Takahashi Y; Motoo Y; Kawakami K; Minamoto T
    Oncology; 2006; 71(3-4):297-305. PubMed ID: 17652946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain.
    Soutar MP; Kim WY; Williamson R; Peggie M; Hastie CJ; McLauchlan H; Snider WD; Gordon-Weeks PR; Sutherland C
    J Neurochem; 2010 Nov; 115(4):974-83. PubMed ID: 20831597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homology modeling and molecular dynamics study of GSK3/SHAGGY-like kinase.
    Xiao JF; Li ZS; Sun M; Zhang Y; Sun CC
    Comput Biol Chem; 2004 Jul; 28(3):179-88. PubMed ID: 15261148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.